SCHEMBL17969016

SCHEMBL17969016

O=Cc1ccc(OS(=O)(=O)C(F)(F)F)c(/C=C/c2cccc(C(F)(F)F)c2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NFE2L2 Q16236 1/20 0.45
▸ FBP1 P09467 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ PTGES2 Q9H7Z7 3/20 0.37
▸ CHRNB2 P17787 1/20 0.37
▸ CHRNB4 P30926 1/20 0.37
▸ CHRNA3 P32297 1/20 0.37
▸ CHRNA7 P36544 1/20 0.37
▸ CHRNA4 P43681 1/20 0.37
▸ P4HB P07237 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ HSP90AA1 P07900 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ MAOB P27338 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16398906 1.00 NFE2L2 (0.45) NFE2L2FBP1ALDH1A1POLBL3MBTL1
SCHEMBL26425426 0.93 NFE2L2 (0.47) NFE2L2FBP1PTGES2CHRNB2CHRNB4
SCHEMBL16399353 0.88 NFE2L2 (0.48) NFE2L2FBP1ALDH1A1POLBL3MBTL1
SCHEMBL16399350 0.88 NFE2L2 (0.48) NFE2L2FBP1ALDH1A1POLBL3MBTL1
SCHEMBL28960351 0.84 PTGS1 (0.37) NFE2L2ALDH1A1
SCHEMBL26426000 0.84 PTGS1 (0.37) NFE2L2ALDH1A1
SCHEMBL26426007 0.82 PTGS1 (0.47) NFE2L2FBP1CA1CA2CA9
SCHEMBL26425423 0.81 CYP1A1 (0.42) NFE2L2ALDH1A1LMNAMAOB
SCHEMBL18003166 0.80 NFE2L2 (0.49) NFE2L2FBP1ALDH1A1POLBL3MBTL1
SCHEMBL26425416 0.80 NFE2L2 (0.47) NFE2L2FBP1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4570313-A2 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2025-06-18 — — EP disclosed
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 — — EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 — — US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 NFE2L2 1380/4885FBP1 298/4885ALDH1A1 1611/4885
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS CS, PC, ACAT1 NFE2L2 1380/4885FBP1 298/4885ALDH1A1 1611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback